secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001193125-22-215574
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera reports Q2 net loss $14.6M ($0.54/sh); NDA for avasopasem on track by end of 2022
--------------------------------------------------------------------------------

- Net loss $14.6M ($0.54 per share) in Q2 2022, compared to $22.4M ($0.88/sh) in Q2 2021.
- R&D expenses $6.7M (down from $16.0M YoY); cash and investments $52.0M as of June 30, 2022.
- Phase 3 ROMAN data: avasopasem reduced SOM incidence and days; NDA submission on track for end of 2022.
- Phase 1 GRECO-1: rucosopasem+SBRT showed 6/7 patients with partial response or stable disease; Phase 2 enrollment completion expected 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312522215574/0001193125-22-215574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312522215574/d375942d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-215574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer